Literature DB >> 30986128

The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer.

Rowa Bakadlag1,2, Pouria Jandaghi1,2, Jörg D Hoheisel3, Yasser Riazalhosseini1,2.   

Abstract

Entities:  

Keywords:  Cancer; DRD2; chemotherapy; drug-repositioning; haloperidol; pancreatic ductal adenocarcinoma; pimozide

Mesh：

Substances：

Year:  2019        PMID： 30986128     DOI： 10.1080/14728222.2019.1606904

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  3 in total

Review 1.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

2.  Exploring the Molecular Mechanism of Astragali Radix-Curcumae Rhizoma against Gastric Intraepithelial Neoplasia by Network Pharmacology and Molecular Docking.

Authors:  Yuejin Ji; Yajun Liu; Jingyi Hu; Cheng Cheng; Jing Xing; Lei Zhu; Hong Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-04       Impact factor: 2.629

3.  Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.

Authors:  Wen Hu; Li Zhang; Sammy Ferri-Borgogno; Suet-Ying Kwan; Kelsey E Lewis; Han T Cun; Tsz-Lun Yeung; Pamela T Soliman; Rohinton S Tarapore; Joshua E Allen; Xinyuan Guan; Karen H Lu; Samuel C Mok; Chi-Lam Au-Yeung
Journal:  Cancers (Basel)       Date:  2020-08-27       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.